Influence of Renal Impairment on the Pharmacokinetics of Afatinib: An Open-Label, Single-Dose Study

被引：0
|
作者：
Sabrina Wiebe
David Schnell
Raimund Külzer
Dietmar Gansser
Anne Weber
Gudrun Wallenstein
Atef Halabi
Anja Conrad
Sven Wind
机构：
[1] Boehringer Ingelheim Pharma GmbH & Co KG,Translational Medicine and Clinical Pharmacology
[2] Datamap GmbH,undefined
[3] Clinical Research Services (CRS) Kiel GmbH,undefined
来源：
European Journal of Drug Metabolism and Pharmacokinetics | 2017年 / 42卷
关键词：
Renal Impairment; Epidermal Growth Factor Receptor Mutation; Plasma Protein Binding; Severe Renal Impairment; Advanced Solid Tumour;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：461 / 469
页数：8
相关论文
共 50 条
  • [31] Maribavir Pharmacokinetics and Safety in Participants With Moderate Hepatic Impairment: A Phase 1, Open-Label, Single-Dose, Parallel Group Study
    Song, Ivy
    Chen, Grace
    Wu, Jingyang
    Ilic, Katarina
    JOURNAL OF CLINICAL PHARMACOLOGY, 2023, 63 (02): : 250 - 258
  • [32] Phase 1, open-label, single-dose study to evaluate the effect of hepatic impairment on the pharmacokinetics and safety of futibatinib in adult subjects
    Gao, Ling
    Yamamiya, Ikuo
    Pinti, Mark
    Rondon, Juan Carlos
    Gareth, Thomas Marbury
    Tomlinson, Gareth
    Makris, Lukas
    Hangai, Nanae
    Wacheck, Volker
    CANCER RESEARCH, 2023, 83 (08)
  • [33] Pharmacokinetics of tamsulosin in subjects with normal and varying degrees of impaired renal function: an open-label single-dose and multiple-dose study
    Wolzt, M
    Fabrizii, V
    Dorner, GT
    Zanaschka, G
    Leufkens, P
    Krauwinkel, WJJ
    Eichler, HG
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 54 (04) : 367 - 373
  • [34] Pharmacokinetics of tamsulosin in subjects with normal and varying degrees of impaired renal function: an open-label single-dose and multiple-dose study
    M. Wolzt
    V. Fabrizii
    G. T. Dorner
    G. Zanaschka
    P. Leufkens
    W. J. J. Krauwinkel
    H.-G. Eichler
    European Journal of Clinical Pharmacology, 1998, 54 : 367 - 373
  • [35] Pharmacokinetics of serelaxin in patients with severe renal impairment or end-stage renal disease requiring hemodialysis: A single-dose, open-label, parallel-group study
    Dahlke, Marion
    Halabi, Atef
    Canadi, Jasna
    Tsubouchi, Chiaki
    Machineni, Surendra
    Pang, Yinuo
    JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 56 (04): : 474 - 483
  • [36] Pharmacokinetics and pharmacodynamics of cinacalcet in hepatic impairment - Phase I, open-label, parallel-group, single-dose, single-centre study
    Padhi, Desmond
    Harris, Robert Z.
    Salfi, Margaret
    Noveck, Robert J.
    Sullivan, John T.
    CLINICAL DRUG INVESTIGATION, 2008, 28 (10) : 635 - 643
  • [37] Influence of renal impairment on the pharmacokinetics of oral roflumilast: an open-label, parallel-group, single-center study
    Bethke, T. D.
    Hartmann, M.
    Huennemeyer, A.
    Lahu, G.
    Gleiter, C. H.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2011, 49 (08) : 491 - 499
  • [38] Single-Dose Pharmacokinetics and Safety of Atogepant in Adults With Hepatic Impairment: Results From an Open-Label, Phase 1 Trial
    Boinpally, Ramesh
    Jakate, Abhijeet
    Butler, Matthew
    Borbridge, Lisa
    Periclou, Antonia
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2021, 10 (07): : 726 - 733
  • [39] Effect of hepatic impairment on sorafenib pharmacokinetics: Results of a multicenter, open-label, single-dose, phase I trial.
    Lettieri, J. T.
    Mazzu, A. L.
    Huang, L.
    Lathia, C. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [40] Single-Dose Pharmacokinetics and Safety of Ubrogepant in Adults With Hepatic Impairment: Results From an Open-Label, Phase 1 Trial
    Boinpally, Ramesh
    Lu, Kaifeng
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2022, 11 (07): : 857 - 864
12345